All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
AML World Awareness Day | Recent advances in AML treatment options
Bookmark this article
There are a number of treatment options for patients with AML in its various forms and stages. The most common treatment regimen begins with the induction phase when symptoms are treated and leukemic cells are destroyed. Often, the induction phase consists of intensive chemotherapy, with the consolidation phase of the therapy beginning when there is no sign of the cancer. This stage is to ensure the prevention of relapse.
This treatment regimen can vary, with patients who are not suitable for intensive chemotherapy being given less intensive chemotherapy, and some patients receiving radiotherapy to prepare the body for transplant.
Recent advances focus on how to optimize current treatments to enable to best possible outcome. Ali Bazarbachi, from the American University of Beirut Medical Center, Beirut, LE, gave us an expert view on maintenance treatment after stem cell transplantation:
Maintenance treatment after stem cell transplantation
At EBMT 2019 in Frankfurt, Germany, Richard Stone from the Dana-Farber Cancer Institute, Boston, US, talked about the role of FLT3 inhibitors in the treatment of AML:
Role of FLT3 inhibitors in the treatment landscape of AML
With up to 75% of patients allografted for AML poised for relapse, and fewer than 10% surviving long-term, only patients who achieve a second complete remission (CR) with salvaged chemotherapy after allogenic stem cell transplantation (allo-SCT) have encouraging long-term survival. At the 45th Annual Meeting of the European Society for Blood and Marrow Transplantation, in Frankfurt, Germany, Charlie Craddock, from the Centre for Clinical Haematology, Queen Elizabeth Hospital Birmingham, University of Birmingham, presented an educational session on strategies to optimize the GVL effect in AML patients.
Also at EBMT 2019, Maria Queralt Salas from Princess Margaret Cancer Centre, Hans Messner Allogeneic BMT Program, Toronto, Canada, outlined a study investigating graft-versus-host disease prophylaxis with a reduced intensity conditioning regimen combined with anti-thymocyte globulin and post-transplantation cyclophosphamide for AML.
At the Acute Leukemias XVII Biology and Treatment Strategies biennial international symposium in Munich, Germany, the latest developments in targeted therapies for AML were widely discussed among experts, with a focus on FLT3-ITD AML. Sorafenib was highlighted to be a salvage therapy for adult patients with FLT3-ITD AML, with overall survival being significantly improved in patients who had undergone relapse or disease progression.
Laura Michaelis from the Medical College of Wisconsin, Milwaukee, US, spoke of the use of cytotoxic induction therapy in acute myeloid leukemia (AML) at the 60th Annual Meeting of the American Society of Hematology (ASH). She argued that it is too early to get rid of cytotoxic therapy in AML:
Moving beyond 7 + 3 in acute myeloid leukemia
The AML Global Portal has highlighted advances in the treatments for AML over the last few years, and will continue to look out for emerging therapies, providing a platform to increase awareness of AML globally. Please visit www.know-aml.com to find out more information about AML World Awareness Day.
Your opinion matters
15 votes - 78 days left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox